The worksheets include data for all ICBs and GP practices in England within the May 2025 extraction of NDA data (April 2024 to March 2025 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. Data for Local Health Boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2024-25 data (for the full audit period April 2024 to March 2025) will be extracted as part of the final NDA 2024-25 collection and reported in the NDA 2024-25 full audit period data release, scheduled for late 2025. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available. Percentages where the denominator is less than or equal to 20 are not reliable and have therefore not been calculated in this release.

The size of the United Kingdom Self-Monitoring Blood Glucose Market was valued at USD 273.34 Million in 2023 and is projected to reach USD 379.52 Million by 2032, with an expected CAGR of 4.80% during the forecast period. The United Kingdom Self-Monitoring Blood Glucose market is an emerging segment in the health industry. Self-monitoring blood glucose, shortened as SMBG, is a process of self-monitoring of blood sugar in the home of an individual by using a glucometer, that is, a small hand-held device. For patients suffering from diabetes, this serves to be a very important tool in the efficient management of their condition because it helps them understand the fluctuations occurring in the blood sugar at various points in the day. SMBG involves drawing a thin small drop of blood by using a finger prick. That drop of blood is then applied to the test strip, which is placed within the glucometer. It calculates the blood sugar reading in no time and prints it out. With the help of SMBG, one can monitor the level of blood sugar and take sound decisions accordingly regarding their insulin dosing, diet, and exercises. This makes it easy for them to shun complications such as hypoglycemia- low blood sugar and hyperglycemia- high sugar levels in the blood which might lead to serious health conditions if they aren't checked. Growth drivers for the SMBG market in the United Kingdom include an increased prevalence of diabetes, mainly type 2, which is on the rise globally because of reasons such as obesity and a sedentary lifestyle. Improved glucometer technology, now including CGM systems, also bring SMBG as close to the patient as possible and convenient for patients. The CGM device never stops tracking blood sugar, and there are no painful finger pricks; it provides continuous real-time information to allow improved management of diabetes. Recent developments include: January, 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 20, 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held COBAS Pulse includes an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It's designed to be used with patients of all ages, including neonates and people in intensive care.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Rising Diabetes Prevalence in the United Kingdom.

The European blood glucose monitoring market, valued at €3.14 billion in 2025, is projected to experience robust growth, driven by the rising prevalence of diabetes across the region. A compound annual growth rate (CAGR) of 6.38% from 2025 to 2033 indicates a significant market expansion, fueled by several key factors. Increased awareness of diabetes management, coupled with advancements in technology leading to more accurate and user-friendly glucometers, test strips, and lancets, are primary drivers. The aging population in Europe, a significant risk factor for diabetes, further contributes to market growth. Furthermore, the increasing adoption of continuous glucose monitoring (CGM) systems, offering real-time data and improved patient management, is expected to significantly impact market segmentation and growth trajectory over the forecast period. However, high costs associated with CGM technology and the availability of less expensive alternative monitoring methods might act as market restraints to some extent. The market is segmented by component into glucometer devices, test strips, and lancets, with significant variations in market share among these components. Leading players like Abbott Diabetes Care, Roche Diabetes Care, and LifeScan, hold substantial market shares, leveraging their established brand recognition and extensive distribution networks. The market demonstrates a strong regional disparity within Europe, with countries like Germany, France, and the UK likely contributing the largest shares, driven by higher diabetes prevalence and better healthcare infrastructure compared to other regions. The competitive landscape is characterized by both established multinational companies and smaller regional players. Strategic alliances, mergers and acquisitions, and technological innovation are prominent strategies employed by market players to gain a competitive edge. The forecast period from 2025 to 2033 promises sustained growth, propelled by the continued rise in diabetes prevalence and the ongoing development of innovative blood glucose monitoring technologies. While pricing pressures and regulatory hurdles may present challenges, the overall outlook for the European blood glucose monitoring market remains positive, promising significant opportunities for market participants. Further analysis of specific regional markets (France, Germany, Italy, Spain, UK, Russia, and Rest of Europe) would provide granular insights into market dynamics and inform targeted strategies. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published improved glycemic control using a Bluetooth-connected blood glucose meter and a mobile diabetes app: Real-World Evidence from over 144,000 people with diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held Cobas pulse includes an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It's designed to be used with patients of all ages, including neonates and people in intensive care.. Notable trends are: Increasing Diabetes Prevalence is Driving the Europe self-monitoring Blood Glucose Devices Market in forecast period.